
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated significant growth potential through its TissueCypher test, which experienced a remarkable 92% year-over-year increase in test volume in the second quarter of 2025, reflecting strong adoption and market demand. The company anticipates that the gastrointestinal sales force will reach maturity by the second half of 2025, further supporting revenue growth as the company continues to enhance gross margins, which for TissueCypher reached an impressive 77% in the third quarter. These fundamental metrics, along with the ongoing expansion of the sales force, position Castle Biosciences favorably for sustained financial performance and market share growth in the molecular diagnostics sector.
Bears say
Castle Biosciences Inc. faces a negative outlook primarily due to anticipated EV-to-estimated 2026/2027 revenue multiples for its dermatology and DecisionDx-UM tests being projected to be considerably lower than those for its TissueCypher product. Despite the company’s management indicating minimal clinician pushback during the Q3'24 call, a significant concern persists regarding the low levels of clinician awareness, particularly in the gastrointestinal space, which could hinder test adoption and revenue growth. Furthermore, while the stock may appear undervalued based on conservative estimates, the underlying penetration challenges for key tests suggest that financial performance may not improve as anticipated in the near term.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares